Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has received an average recommendation of “Reduce” from the twelve ratings firms that are covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $8.20.
Several brokerages have commented on FULC. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, October 15th. Wall Street Zen upgraded Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday.
View Our Latest Stock Report on FULC
Fulcrum Therapeutics Stock Up 2.4%
Shares of FULC stock traded up $0.09 during mid-day trading on Friday, reaching $3.77. 1,364,507 shares of the company’s stock traded hands, compared to its average volume of 1,300,025. Fulcrum Therapeutics has a 12 month low of $2.83 and a 12 month high of $15.74. The company has a market cap of $287.95 million, a P/E ratio of -3.62 and a beta of 2.82. The company’s 50-day moving average price is $3.73 and its 200-day moving average price is $5.55.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). Equities analysts predict that Fulcrum Therapeutics will post -0.60 earnings per share for the current year.
Institutional Trading of Fulcrum Therapeutics
Several large investors have recently modified their holdings of the company. FORA Capital LLC purchased a new stake in Fulcrum Therapeutics in the third quarter worth about $101,000. Marshall Wace LLP lifted its position in shares of Fulcrum Therapeutics by 39.4% during the 3rd quarter. Marshall Wace LLP now owns 1,893,289 shares of the company’s stock valued at $7,005,000 after buying an additional 534,866 shares in the last quarter. Empowered Funds LLC purchased a new position in shares of Fulcrum Therapeutics during the 3rd quarter valued at about $329,000. Nantahala Capital Management LLC lifted its position in shares of Fulcrum Therapeutics by 20.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 6,575,352 shares of the company’s stock valued at $24,329,000 after buying an additional 1,100,312 shares in the last quarter. Finally, Alps Advisors Inc. grew its stake in shares of Fulcrum Therapeutics by 48.4% during the 3rd quarter. Alps Advisors Inc. now owns 100,366 shares of the company’s stock valued at $371,000 after acquiring an additional 32,734 shares during the period. Institutional investors own 89.83% of the company’s stock.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.
See Also
- Five stocks we like better than Fulcrum Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
